论文部分内容阅读
目的:总结肺鳞状细胞癌分子特征改变的研究现状及相关临床试验结果,探讨肺鳞癌的个体化治疗策略。方法:应用PubMed、CBM、CNKI和Medline数据库检索系统,以“肺鳞状细胞癌、突变、过表达、扩增和临床试验”及相关因子名称为关键词,检索2000-01-2012-08的相关文献。纳入标准:1)肺鳞癌细胞存在的分子生物学改变;2)相关靶向治疗药物的临床试验进展。符合分析的文献27篇。结果:肺鳞癌细胞的一组分子特征改变在肺鳞癌发生发展过程中发挥了重要作用,根据治疗靶点的不同,可分为膜受体、信号通路分子和转录因子3类,其中膜受体包括FGFR1、IGF-1R、EGFRvⅢ、PDGFRA、DDR2和MET;信号通路分子包括PIK3CA、AKT1、PTEN和B-RAF;转录因子包括SOX2和Nrf2;基于这些靶点的靶向治疗药物陆续进入临床试验阶段并取得了一定的进展。结论:在肺鳞癌的诊治中,分子特征的检测应受到更多的重视,分子特征改变的研究不仅有助于明确肿瘤的生物学特性,而且可以为患者选择更加合理的、个体化的治疗方案。
Objective: To summarize the research status of molecular features of lung squamous cell carcinoma and related clinical trial results, and to explore the individualized treatment strategies for squamous cell carcinoma of the lung. Methods: Using PubMed, CBM, CNKI and Medline database search system, with the key words of “lung squamous cell carcinoma, mutation, overexpression, amplification and clinical trial” and related factor names, 08 related articles. Inclusion criteria: 1) Molecular biological changes in lung squamous cell carcinoma; 2) Progress in clinical trials of targeted therapies. Accord with the analysis of 27 articles. Results: A set of molecular characteristics of lung squamous carcinoma cells play an important role in the development of lung squamous cell carcinoma. According to different therapeutic targets, they can be divided into three types: membrane receptors, signaling molecules and transcription factors Receptors include FGFR1, IGF-1R, EGFRvIII, PDGFRA, DDR2 and MET; signaling pathway molecules including PIK3CA, AKT1, PTEN and B-RAF; transcription factors including SOX2 and Nrf2; and targeted therapies based on these targets Experimental stage and made some progress. Conclusion: In the diagnosis and treatment of squamous cell carcinoma of the lung, more attention should be paid to the detection of molecular characteristics. The study of molecular characteristics not only helps to clarify the biological characteristics of tumors, but also to select more rational and individualized treatment for patients Program.